Keywords: Roche, Genentech, Vismodegib, Erivedge, Curis, USA, FDA, Basal cell carcinoma

Faster-than-expected FDA approval of Roche’s vismodegib

Article | 31 January 2012

Print This

There was good news for Swiss drug major Roche's (ROG: SIX) subsidiary Genentech yesterday, when it received approval ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in